Herpes zoster vaccine: A health economic evaluation for Switzerland

References

• Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (Shingles) and postherpetic neuralgia. Am Fam Physician 2000; 61:2437-48; PMID:10794584
   PubMed Web of Science ®Google Scholar
• Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002; 19(5):471-5; PMID:12356697; https://doi.org/10.1093/fampra/19.5.471
   PubMed Web of Science ®Google Scholar
• Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, Breuer J. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70(Suppl 1):S24-30; PMID:12627483; https://doi.org/10.1002/jmv.10316
   PubMedGoogle Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352(22):2271-84; PMID:15930418; https://doi.org/10.1056/NEJMoa051016
   PubMed Web of Science ®Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18(6):350-4; PMID:12441828; https://doi.org/10.1097/00002508-200211000-00002
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67(2–3):241-51; PMID:8951917; https://doi.org/10.1016/0304-3959(96)03122-3
   PubMed Web of Science ®Google Scholar
• Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6(6):356-63; PMID:15943957; https://doi.org/10.1016/j.jpain.2005.01.359
   PubMed Web of Science ®Google Scholar
• Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39(3):342-8; PMID:15307000; https://doi.org/10.1086/421942
   PubMed Web of Science ®Google Scholar
• Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013; 13:170; PMID:23574765; https://doi.org/10.1186/1471-2334-13-170
   PubMed Web of Science ®Google Scholar
• Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155(15):1605-9; PMID:7618983; https://doi.org/10.1001/archinte.1995.00430150071008
   PubMed Web of Science ®Google Scholar
• Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin 2011; 7(7):749-56; PMID:21606685; https://doi.org/10.4161/hv.7.7.15573
   PubMed Web of Science ®Google Scholar
• Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25(157):571-5; PMID:1195231
   PubMedGoogle Scholar
• Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55(10):1320-8; PMID:22828595; https://doi.org/10.1093/cid/cis638
   PubMed Web of Science ®Google Scholar
• Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60(6):900-9; PMID:25416754; https://doi.org/10.1093/cid/ciu918
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308(1):43-9; PMID:22760290; https://doi.org/10.1001/jama.2012.7304
   PubMed Web of Science ®Google Scholar
• Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013; 10(4):e1001420; PMID:23585738; https://doi.org/10.1371/journal.pmed.1001420
   PubMed Web of Science ®Google Scholar
• EMA. European Medicines Agency: Zostavax; zoster vaccine (live)
   Google Scholar
• Vionnet J, Hart K, Spertini F. Vaccin contre le zona : quelles recommandations en 2014? Rev Med Suisse 2014; 426:869-75
   Google Scholar
• BAG. Bundesamt für Gesundheit: Vaccination contre le zona: pas d'introduction dans le plan suisse de vaccination. Bulletin OFSP. 2010:97-101
   Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54(7):922-8; PMID:22291101; https://doi.org/10.1093/cid/cir970
   PubMed Web of Science ®Google Scholar
• Pellissier JM. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25:8326-37; PMID:17980938; https://doi.org/10.1016/j.vaccine.2007.09.066
   PubMed Web of Science ®Google Scholar
• Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 1998; 51(8):667-76; PMID:9743315; https://doi.org/10.1016/S0895-4356(98)00036-5
   PubMed Web of Science ®Google Scholar
• Van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27(9):1454-67; PMID:19135492; https://doi.org/10.1016/j.vaccine.2008.12.024
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19(23–24):3076-90; PMID:11312002; https://doi.org/10.1016/S0264-410X(01)00044-5
   PubMed Web of Science ®Google Scholar
• Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2008, 137(1):38-47; PMID:18466661; https://doi.org/10.1017/S0950268808000678
   PubMed Web of Science ®Google Scholar
• Michel JP, Kempf W. Data collection related to the management of herpes zoster (HZ) and post-herpetic neuralgia (PHN) and demographic parameters in Switzerland. 2007
   Google Scholar
• National Institute for Health and Clinical Excellence. www.nice.org.uk 2009
   Google Scholar
• Organization., W.H. Cost-effectiveness thresholds. 2015
   Google Scholar
• Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008; 24(5):1473-83; PMID:18413014; https://doi.org/10.1185/030079908X297826
   PubMed Web of Science ®Google Scholar
• Li X, Zhang JH, Betts RF, Morrison VA, Xu R, Itzler RF, Acosta CJ, Dasbach EJ, Pellissier JM, Johnson GR, et al. Modeling the durability of ZOSTAVAX(R) vaccine efficacy in people >/=60 years of age. Vaccine 2015; 33(12):1499-505; PMID:25444784; https://doi.org/10.1016/j.vaccine.2014.10.039
   PubMed Web of Science ®Google Scholar
• Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health 2015; 15:533; PMID:26041469; https://doi.org/10.1186/s12889-015-1861-8
   PubMed Web of Science ®Google Scholar
• Uhart M, Préaud E, Brandao A, Silva AP, Vandewalle B, Félix J. Herpes Zoster and Post-Herpetic Neuralgia Vaccination- Cost-Effectiveness Analysis In Portugal. Value Health 2015; 18(7):A584; PMID:26533283; https://doi.org/10.1016/j.jval.2015.09.1960
   PubMed Web of Science ®Google Scholar
• Belchior E, Lévy-Bruhl D, Le Strat Y, Herida M. Cost-effectiveness of a herpes zoster vaccination program among the French elderly people. Hum Vaccin Immunother 2016; 12(9):2378-82; PMID:27484158; https://doi.org/10.1080/21645515.2016.1184801
   PubMed Web of Science ®Google Scholar
• Coretti S CP, Romano F, Ruggeri M, Cicchetti A. COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS. Int J Technol Assess Health Care 2016; 32(4):233-40; PMID:27624398; https://doi.org/10.1017/S0266462316000337
   PubMed Web of Science ®Google Scholar
• College voor Zorgverzekeringen (CVZ). GVS-rapport 14/06: herpes zoster vaccine (Zostavax®). 2014
   Google Scholar
• HAUTE AUTORITE DE SANTE: Transprency Committee opinion on Zostavax
   Google Scholar
• Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc 2010; 8:7; PMID:20433704; https://doi.org/10.1186/1478-7547-8-7
   PubMedGoogle Scholar
• Annemans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ 2010; 13(3):537-51; PMID:20707768; https://doi.org/10.3111/13696998.2010.502854
   PubMedGoogle Scholar
• Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2013; 13(3):393-406; PMID:23537397; https://doi.org/10.1586/erp.13.19
   PubMed Web of Science ®Google Scholar
• Preaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin Immunother 2015; 11(4):884-96; PMID:25933182; https://doi.org/10.1080/21645515.2015.1011561
   PubMed Web of Science ®Google Scholar
• Lopez-Belmonte JL, Cisterna R, Gil de Miguel A, Guilmet C, Bianic F, Uhart M. The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older. J Med Econ 2016; 19(6):576-86; PMID:26808422; https://doi.org/10.3111/13696998.2016.1146726
   PubMed Web of Science ®Google Scholar
• Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics 2013; 31(2):125-36; PMID:23335045; https://doi.org/10.1007/s40273-012-0020-7
   PubMed Web of Science ®Google Scholar
• Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine 2014; 32(15):1645-53; PMID:24534737; https://doi.org/10.1016/j.vaccine.2014.01.058
   PubMed Web of Science ®Google Scholar
• Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine 2012; 30(17):2795-800; PMID:21964056; https://doi.org/10.1016/j.vaccine.2011.09.079
   PubMed Web of Science ®Google Scholar
• Kohli R. Swiss Federal Statistical Office: Szenarien zur Bevölkerungsentwicklung der Schweiz 2015–2045. 2015
   Google Scholar
• Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract 2011; 61(582):e12-21; PMID:21401985; https://doi.org/10.3399/bjgp11X548929
   PubMed Web of Science ®Google Scholar
• Council of the European Union - Note from Presidency to Permanent Representatives Committee/Council. Investing in Health: The ‘Missing Dimension’ of the Europe 2020. 2016
   Google Scholar
• Lang PO, Aspinall R. Vaccination in the elderly: what can be recommended? Drugs Aging 2014; 31(8):581-99; PMID:24928553; https://doi.org/10.1007/s40266-014-0193-1
   PubMed Web of Science ®Google Scholar
• Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005; 23(7):639-49; PMID:16173156; https://doi.org/10.2165/00019053-200523070-00001
   PubMed Web of Science ®Google Scholar
• Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a thought experiment. J Epidemiol Community Health 2001; 55(2):123-5; PMID:11154251; https://doi.org/10.1136/jech.55.2.123
   PubMed Web of Science ®Google Scholar
• BFS Swiss Federal Statistical Office: Permanent resident population by age, sex and category of citizenship, on 31.12.2013. 2014
   Google Scholar
• BFS. Swiss Federal Statistical Office: Mortality, all causes of death. 2014
   Google Scholar
• BAG Federal Office of Public Health: The Swiss Sentinel Surveillance Network. 2015
   Google Scholar
• Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003; 326(7392):748-50; PMID:12676845; https://doi.org/10.1136/bmj.326.7392.748
   PubMed Web of Science ®Google Scholar
• Nagasako EM, Johnson RW, Griffin DR, Dworkin RH. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. J Am. Acad Dermatol 2002; 46(6):834-9; PMID:12063479; https://doi.org/10.1067/mjd.2002.120924
   PubMed Web of Science ®Google Scholar
• Merck Data on File. 2006
   Google Scholar
• Health Survery for England 2012. 2012
   Google Scholar
• BFS. Swiss Federal office of statistics: Kaufkraftparitäten – Daten, Indikatoren Preisniveauindizes. 2014; Available from: http://www.bfs.admin.ch/bfs/portal/de/index/themen/05/07/blank/key/01.html
   Google Scholar
• BFS. Swiss Federal Statistical Office: Medical Statistics of hospitals 2013. 2013
   Google Scholar